Experienced in Thyroid Eye Disease

Dr. Amir Tirosh

Endocrinology
221 Longwood Ave, 2nd Floor, 
Boston, MA 
Experienced in Thyroid Eye Disease
221 Longwood Ave, 2nd Floor, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amir Tirosh is an Endocrinologist in Boston, Massachusetts. Dr. Tirosh is rated as an Experienced provider by MediFind in the treatment of Thyroid Eye Disease. His top areas of expertise are Type 2 Diabetes (T2D), Obesity, Low Blood Sugar, and Obesity in Children.

His clinical research consists of co-authoring 95 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Thyroid Eye Disease.

Specialties
Endocrinology
Licenses
Internal Medicine in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

221 Longwood Ave, 2nd Floor, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Semaglutide
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

95 Total Publications

Thyroid, Celiac, and Other Autoimmune Diseases and the Risk of Incident Type 1 Diabetes in Young Adulthood.
Thyroid, Celiac, and Other Autoimmune Diseases and the Risk of Incident Type 1 Diabetes in Young Adulthood.
Journal: Diabetes care
Published: June 14, 2025
Similar Doctors
Advanced in Thyroid Eye Disease
Dr. Giuseppe Barbesino
Endocrinology
Advanced in Thyroid Eye Disease
Dr. Giuseppe Barbesino
Endocrinology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Giuseppe Barbesino is an Endocrinologist in Boston, Massachusetts. Dr. Barbesino is rated as a Distinguished provider by MediFind in the treatment of Thyroid Eye Disease. His top areas of expertise are Thyroid Cancer, Graves Disease, Follicular Thyroid Cancer, and Thyroid Nodule.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tirosh's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile